- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1950
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Risankizumab: A Review in Moderate to Severe Plaque Psoriasis ; volume:80 ; number:12 ; day:6 ; month:7 ; year:2020 ; pages:1235-1245 ; date:8.2020
Drugs ; 80, Heft 12 (6.7.2020), 1235-1245, 8.2020
- Urheber
-
Blair, Hannah A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40265-020-01357-1
- URN
-
urn:nbn:de:101:1-2020111320202243747377
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Blair, Hannah A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Oral microbiota diversity in moderate to severe plaque psoriasis, nail psoriasis and psoriatic arthritis
Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil
Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
Dose Adjustment of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in the Real World: A Systematic Review
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness Study
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis
A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Oral microbiota diversity in moderate to severe plaque psoriasis, nail psoriasis and psoriatic arthritis
Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil
Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
Dose Adjustment of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in the Real World: A Systematic Review
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness Study
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis
A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Oral microbiota diversity in moderate to severe plaque psoriasis, nail psoriasis and psoriatic arthritis
Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil
Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
Dose Adjustment of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in the Real World: A Systematic Review
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness Study
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis
A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis